Changes in global longitudinal strain with mAb CAEL-101 in patients with cardiac involvement enrolled in phase 1b (n = 10; blue lines). This figure highlights cardiac response assessment based on measurement of myocardial function at baseline and week 12 using speckle-tracking (TomTec-Arena 1.2) and calculated as an average of 4-, 2-, and 3- chamber based measurements in cardiac response evaluable patients. Nineteen patients were enrolled in the phase 1b study and 10/19 patients were evaluable for cardiac response. NT-proBNP (pg/mL) is included for each patient at baseline (left) and at week 12 (right). An improvement of 2 units (a decrease by −2) is a clinically significant improvement in strain in the AL amyloidosis population. Mean GLS improved significantly in 9/10 patients from −15.58% ± −4.14% at screening to −17.37% ± −3.53% at week 12, P = .004. Pearson correlation coefficient between NT-proBNP response and GLS response (in 8 cardiac evaluable patients) was 0.345, which supports correlation of 2 markers of organ response.